What changed from existing technology?
This study tested a combination of l-glutamine with standard chemotherapy drugs for advanced pancreatic cancer, finding it safe and showing some early signs of effectiveness.
This is the first clinical trial to evaluate the combination of l-glutamine with standard chemotherapy for pancreatic cancer, showing potential for further investigation.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
atic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial. Exogenous l-glutamine has preclinical antitumor activity although formal clin
Title ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This combination may be explored further for its potential in treating advanced pancreatic cancer, though more research is needed.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.